Review highlights advancements in 3D models for liver fibrosis, suggesting improved disease modeling and drug testing.
Liver fibrosis (LF) is a progressive and increasingly prevalent condition, yet current therapeutic options remain limited. This underscores the growing demand for advanced three-dimensional (3D) preclinical models that better recapitulate the complex pathophysiology of human LF and overcome the limitations of conventional systems. Although a number of in vitro models have been proposed in recent years, many still rely on two-dimensional (2D) hepatocyte cultures, which fail to represent the multicellular interactions and spatial architecture of the fibrotic liver. In contrast, 3D in vitro models, including spheroids, organoids, and liver-on-a-chip (LoC) platforms, offer more physiologically relevant microenvironments, enabling improved disease modeling and patient-specific drug testing. In this review, we summarize current bioengineering strategies for constructing 3D LF models and highlight their advantages, limitations, and future directions for clinical translation.
No takes yet. Share an insight, caveat, or question.
Lee et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: